BEDFORD, Ohio, Jan. 29 /PRNewswire-FirstCall/ -- Bedford Laboratories(TM), a division of Ben Venue Laboratories, Inc., announced the launch of Irinotecan HCl Injection. This product is AP rated and is equivalent to Camptosar(R). Irinotecan is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. This product is available for immediate shipment nationwide.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO )
Bedford Laboratories will supply Irinotecan HCl Injection as a sterile aqueous solution available in two different dosages including 40mg / 2mL single dose amber vials individually boxed and 100mg / 5mL single dose amber vials individually boxed.
Prescribing information is available upon request from the Bedford Laboratories' professional services department at 800.521.5169 or from their web site, www.bedfordlabs.com.
About Bedford Laboratories
Bedford Laboratories supplies the US and international markets with multisource and specialty injectable products. Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc., a subsidiary of Boehringer Ingelheim Corporation located in Ridgefield, CT, and is a part of the Boehringer Ingelheim group of companies.
About Boehringer Ingelheim Corporation
Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and approximately 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2007, Boehringer Ingelheim posted net sales of US $15.0 billion (10.9 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information on the Boehringer Ingelheim Corporation, please visit http://us.boehringer-ingelheim.com.
Camptosar(R) is a registered trademark of Pfizer.
CONTACT: Bedford Laboratories: Jason Kurtz, +1-440-201-3668,
jason.kurtz@boehringer-ingelheim.com
Web site: http://www.bedfordlabs.com/
http://us.boehringer-ingelheim.com/
http://www.benvenue.com/
